Summary:
Phase 3 migraine study involving an injection. It is investigating how effective the medication is in reducing the amount of migraines per month(prevention). The study is 4 months and there is an optional one year open label extension study. The study is 4 months 5 office visits.
Qualified Participants Must:
• Be 18 years of age or older
•
Have a diagnosis of migraines for at least one year
•
Experience at least 6 days of migraines per month
Qualified Participants May Receive:
Compensation for time and travel.